key: cord-1035533-bcco8zew
authors: Kilinç, Gül; Saris, Anno; Ottenhoff, Tom H. M.; Haks, Mariëlle C.
title: Host‐directed therapy to combat mycobacterial infections
date: 2021-02-09
journal: Immunol Rev
DOI: 10.1111/imr.12951
sha: e3f2252b64ac301a5081008de0eca38554907084
doc_id: 1035533
cord_uid: bcco8zew

Upon infection, mycobacteria, such as Mycobacterium tuberculosis (Mtb) and nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering a series of intracellular processes that promote mycobacterial killing. Mycobacteria, however, have developed multiple counter‐strategies to persist and survive inside host cells. By manipulating host effector mechanisms, including phagosome maturation, vacuolar escape, autophagy, antigen presentation, and metabolic pathways, pathogenic mycobacteria are able to establish long‐lasting infection. Counteracting these mycobacteria‐induced host modifying mechanisms can be accomplished by host‐directed therapeutic (HDT) strategies. HDTs offer several major advantages compared to conventional antibiotics: (a) HDTs can be effective against both drug‐resistant and drug‐susceptible bacteria, as well as potentially dormant mycobacteria; (b) HDTs are less likely to induce bacterial drug resistance; and (c) HDTs could synergize with, or shorten antibiotic treatment by targeting different pathways. In this review, we will explore host‐pathogen interactions that have been identified for Mtb for which potential HDTs impacting both innate and adaptive immunity are available, and outline those worthy of future research. We will also discuss possibilities to target NTM infection by HDT, although current knowledge regarding host‐pathogen interactions for NTM is limited compared to Mtb. Finally, we speculate that combinatorial HDT strategies can potentially synergize to achieve optimal mycobacterial host immune control.

HIV infection and use of immunosuppressive medication. Treatment of patients with active TB has largely remained unchanged for over 30 years, 1 and due to its lengthiness (6-24 months) and considerable NTM, including Mav and Mab, express a class of glycolipids known as glycopeptidolipids (GPLs) which mask underlying cell wall phosphatidyl-myo-inositol mannosides, thereby limiting interactions with TLR2. 9, 10 Moreover, the acetylation state of lipomannan modulates TLR2-mediated macrophage activation, and subversion of the TLR2-MyD88 pathway has been linked to phagolysosome escape of virulent Mtb to the cytosol, 11 Mcl-1 inhib.

In vitro Mtb 155 Celecoxib a

In vivo, (R)CT 161 Imatinib a

In vitro Mtb 26, 27 Dexamethasone

In vitro, in vivo, R(CT)

Mtb [157] [158] [159] [160] 188, 191 Vitamin-D

In vitro, (R)CT 18, 19 or miRNA-23a 20 both reduced Mtb survival, identifying miRNA-125 and miRNA-23a as potential targets for HDTs.

After phagocytosis, mycobacteria become localized in phagosomes that are initially non-degradative, but slowly mature into increasingly hostile organelles. This so-called phagosome maturation hinges upon fusion with lysosomes that contain antimicrobial peptides and induce intravesicular acidification enhancing lysosomal enzyme activity. 21 While initially thought to be simply transport vehicles, phagosomes have appeared to be highly dynamic structures that are regulated by several membrane markers, such as PI3P, acidifying proton adenosine triphosphatases (ATPases), and Rab-GTPases. 21, 22 As GTPases are also involved in autophagy induction, these enzymes could be interesting targets for HDT, but as of yet 

Autophagy is a mechanism mediating self-maintenance and cellular homeostasis and is induced under stress such as hypoxia, starvation but also microbial infection. 35 and subsequently delivered to autophagosomes by engagement of membrane-associated LC3. 32 Numerous drugs have been identified that promote autophagy by targeting different components of the autophagic pathways.

Beclin-1 is induced by human antimicrobial peptide (AMP) LL-37, also known as cathelicidin. 38 Cathelicidin is able to suppress Mtb growth and can be induced by pathogens after TLR2/TLR1 ligation, and also by vitamin-D. 39 In vitro experiments identified calcitriol, the bioactive metabolite of vitamin-D, to exert antimicrobial activity by mediating intracellular killing of Mtb through cathelicidin. 40 Calcitriol has also been linked to nitric oxide (NO) production and suppression of matrix metalloproteases (MMPs) which may further protect the host from TB immunopathology. 41, 42 The efficacy of vitamin-D as HDT during TB disease has been investigated in multiple randomized controlled trials (RCTs). Vitamin-D administration corrected any vitamin-D deficiencies and was safe in use but did not show consistent beneficial outcomes during mycobacterial infections in meta-analyses. [43] [44] [45] Acceleration of Mtb clearance from sputum was mainly observed in MDR-TB cases or patients with a specific genotype, such as polymorphisms in the vitamin-D receptor-gene. 46, 47 Furthermore, low levels of vitamin-D have been linked to a higher susceptibility to develop TB disease. 48 Some studies combined vitamin-D therapy with phenylbutyrate (PBA), which stimulates cathelicidin-induced autophagy and also inhibits bacterial growth directly. 49, 50 Combining vitamin-D and PBA treatment further increased expression of cathelicidin in healthy volunteers, but the augmented expression level was constrained to a defined dose range of PBA. 51 The narrow therapeutic window of PBA might clarify why certain RCTs failed to detect accelerated sputum-smear conversion by co-administering vitamin-D and PBA 52 and only showed accelerated sputum-smear conversion at week 4 following combined treatment, but not at week 8 in vitamin-D-deficient patients. 53 Due to these inconsistencies, progression of vitamin-D as potential HDT in TB treatment regimens has not been successful.

Vitamin-A-deficiency has also been correlated with an increased risk to develop TB disease. 54 STING-dependent autophagy can be targeted by the active metabolite of vitamin-A, that is, all-trans retinoic acid (ATRA), which promotes TBK1-mediated enhancement of autophagy which reduces Mtb survival in human macrophages. 55 ATRA is also known to increase CD1d receptor expression on innate immune cells, 56 and treatment with nonmycobacterial CD1d ligand α-galactosylceramide (α-GalCer) reduced mycobacterial load and improved survival of mice with TB, 57 and while α-GalCer combined with ATRA and vitamin-D did not clear the infection in mice, it improved containment of the infection. 58 In patients, vitamin-A supplementation combined with Zn 2+ or vitamin-D gave inconsistent results. 59 Another important negative regulator of autophagy is the PI3K-Akt-mTOR signaling pathway, which is robustly activated by Mtb to facilitate its intracellular survival. 67 Everolimus, an improved analog of mTOR inhibitor rapamycin, was able to reduce Mtb burden in a human granuloma model and these effects were additive to first-line Mtb not only inhibits the initiation of autophagy, but also fusion of autophagosomes with lysosomes via protein P2-PGRS47. 23, 81 Furthermore, the Mtb secretion-factor SapM inhibits Rab7recruitment to prevent autophagosome-lysosome fusion. 82 

To eliminate mycobacteria during infection, host cells trigger the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), via NADPH oxidase 2 (NOX2) 93 and inducible nitric oxide synthase 2 (iNOS), respectively. iNOS catalyzes production of nitric oxide (NO) by converting L-arginine into L-citrulline, which is subsequently converted into RNS. 94 99 and in a guinea pig Mtb infection model N-acetyl-cysteine administration was also shown to be efficacious. 100 Moreover, N-acetyl-cysteine was found to be safe in a cohort of TB-HIV co-infected individuals, 101 although its impact on culture conversion remains to be determined. 101 Nevertheless, ROS production is important for the bactericidal activity of macrophages 102 and the critical balance in ROS production and its regulation is important in restricting intracellular mycobacterial growth without harming the host.

Multiple studies in mice and humans have shown antimicrobial effects of NO, but the exact underlying mechanisms remain unclear. 103 Several Mtb-associated proteins have been identified that protect Mtb from RNS, but Mav naturally tolerates intracellular NO levels and may even benefit from host NO. [110] [111] [112] Mice that cannot produce NO were more resistant to Mav infections, while being more prone to Mtb infections. 113 In agreement with this, compared to wildtype mice, NOS2-deficient mice showed higher IFNγ responses during Mav infection and increased accumulation of especially CD4 + T-cells. 114 Enhancing NO production can thus be beneficial in combatting mycobacterial infections such as Mtb, but not Mav.

Macrophage polarization is an important mechanism of the immune system to respond adequately to the plethora of pathogens, which is partly mediated by epigenetic regulation of gene expression using the above therapies may also be efficacious against NTM.

Upon phagocytosis, pathogens are processed and degraded, such that pathogen-derived peptides can be loaded and presented in MHC-class I and II molecules to initiate adaptive T-cell responses.

One strategy of mycobacteria to evade host adaptive immune responses is to impair presentation of mycobacterial peptides by evading phagosomal degradation. Improving mycobacterial degradation by promoting phagosomal maturation and/or autophagy induction as discussed above likely enhances both antigen presentation and concomitant adaptive immunity. Another strategy of mycobacteria to evade host adaptive immune responses is to predominantly infect macrophages instead of dendritic cells, the former requiring stronger activation before being able to efficiently process and present antigens for priming naive T-cells. 119 Macrophage activation is required to induce expression of CIITA, a major positive regulator of MHC-class II. By actively engaging TLR2 rather than other TLRs, Mtb 131 Blocking IL-4 completely alleviated these effects and improved bacterial control, 131 suggesting Th skewing could be an interesting target for HDT.

Alternatively, administration of IL-2, which stimulates T-cell proliferation while inhibiting T-cell anergy, in patients infected with drug-resistant Mtb has been investigated in five RCTs and compared in a meta-analysis. 146 While CD4 T-cell numbers increased and time to culture conversion improved, radiographic changes were not observed compared to standard chemotherapy. 146 In mice infected with Mav, IL-2 therapy resulted in decreased bacterial burden, 147 whereas mixed results were described in case reports. 148 Furthermore, ferroptosis could also be inhibited by increasing GPX4 levels with selenium, a protein involved in GPX4 catalysis, 173 showing that targeting this host pathway is a potential HDT strategy.

Mtb has developed numerous strategies to modulate host metabolic pathways, which are broadly divided into glycolysis, oxidative phos- on the genotype, different treatment regimens will be required, as general immune suppression using dexamethasone favored outcome in T/T individuals, while being detrimental in C/C individuals, 188, 191 suggesting the necessity of personalized HDT-based medicine targeting eicosanoid metabolism. Mice deficient in 5-lipoxygenase, an enzyme that stimulates production of LTA 4 and thus LTB 4 (thereby being a model for C/C individuals), were impaired in controlling mycobacterial infection due to absence of LTB 4. Treatment with celecoxib, a COX inhibitor that prevents PGE2 production and thereby stimulates LTB 4 production, or directly supplementing LTB 4 , restored mycobacterial control. 187 Furthermore, COX inhibitors ibuprofen and aspirin administered as single therapy or combined with conventional TB antibiotics were shown to limit bacterial burden in

Mtb-infected mice, [192] [193] [194] and low-dose aspirin treatment also reduced bacterial loads in a Mm zebrafish infection model. 195 Aspirin treatment of TB or TB meningitis patients improved survival, 196, 197 but may impair conventional treatment regimens by reducing efficacy of isoniazid, 198 but not pyrazinamide. 193 Inhibition of MMP7 and MMP1 using cipemastat, a drug originally registered to prevent lung fibrosis, surprisingly increased cavitation, immunopathology and mortality in mice, 208 Mm-model. 25 In agreement with this concept, treatment with Sb-3ct, a specific MMP2 and MMP9 inhibitor, combined with frontline TB antibiotics potentiated bacterial clearance both in vitro and in vivo in a TB meningitis mouse model. 212, 213 Blocking MMP9 using monoclonal antibody AB0046 did not affect bacterial burden, but the rate of relapse was reduced in a necrotic granuloma TB mouse model, by mechanisms not yet fully clarified. 166 Using an in vitro model for Both drugs also synergized with first-line anti-mycobacterial drugs rifampicin and metronidazole, a drug that targets hypoxic bacteria. 218 Inhibiting vascular leakage rather than angiogenesis may be equally efficacious to limit nutrient supply to mycobacteria. During with other therapies is likely to be even more potent.

Although HDT could be considered as stand-alone therapy, for example, in patients suffering from total drug-resistant TB, HDT is primarily envisaged as adjunct therapy in combination with classical antibiotics. HDT might be co-administered for a limited duration at the initiation of the standard of care regimens to shorten treatment length and reduce dosage of antibiotics to minimize side effects, or toward the end of treatment to boost host immunity to prevent potential relapse. Consequently, investigating the interactions between HDT and conventional chemotherapy is pivotal, but has only been reported for a limited number of HDTs. Furthermore, in case of undesired interactions between TB drugs and drugs for TB comorbidities (eg, between rifampicin and anti-HIV therapy or antidiabetic drugs), 220 HDT might be used to shorten current treatment regimens or possibly partially replace components of the conventional chemotherapy cocktail. In line with this, interactions between HDT and drugs used to treat TB comorbidities should also be investigated thoroughly.

Rather than targeting one specific aspect of the inflammatory response during mycobacterial infections, we hypothesize that correcting the overall immunological disbalance likely is most promising.

Type-I IFN and IL-1β signaling, regulating levels of anti-inflammatory prostaglandins and pro-inflammatory leukotrienes, respectively, play an important role in regulating the immune balance during mycobacterial infections. 189 At the time of writing, multiple randomized controlled trials investigate targeting of (one of) these pathways by HDTs. has already been shown to reduce TB recurrence and bacterial loads in patients, [75] [76] [77] and in addition to its effects on autophagy, also enhances mitochondrial membrane polarization, 221 which could further enhance its efficacy.

As discussed above, host-cell death pathways are actively exploited by mycobacteria to promote their survival and dissemination and have been shown to be a potential target for HDT in multiple in vitro and animal studies. Active clinical modulation of (programmed) cell death in patients, however, could lead to significant adverse effects given the complex time-and context-dependency of this mechanism during mycobacterial infection.

Targeting metabolic pathways has been shown to be feasible and represents an attractive target for HDT. While most metabolic pathways are also necessary for host-cell energy production, intra- inhibiting VEGF-mediated signaling (SU5416 or pazopanib 218 ), or (c)

antagonizing pro-angiogenesis growth factor ANG2 (AKB-9785 219 ) has all been shown to enhance both drug delivery and oxygenation within granulomas in animal models of TB, and may be promising HDTs in combination with other therapies. Despite being most frequently investigated in combination with antibiotics, efflux pump inhibitors could also improve drug delivery of HDTs. To our knowledge, however, this has not been investigated so far but verapamil, known to enhance the efficacy of rifampicin and bedaquiline against different mycobacterial infections, both in vitro and in mice, [222] [223] [224] and also chloroquine 225 responses with lasting IFNγ production that may be preferred over IFNγ administration. Which of these strategies is (most) efficacious and which patients benefit most from this therapy remains to be addressed.

While most of the evidence available for host-pathogen interactions and HDT are from TB studies, the limited number of NTM experimental models investigating host modulation and/or HDT emphasizes the need and urgency to understand NTM pathogenesis as well as identify potentially relevant host targets. Together, these studies will help assess the safety and efficacy of HDT, paving the way for the introduction of HDT against a wide range of mycobacteria.

We searched PubMed (MEDLINE) for all relevant studies published from 1 January 2000 until 1 October 2020. The medical subject headings used were "host directed", "HDT", "adjunctive", "immunotherapeutic" or "immunomodulation" combined with "mycobacterium", "mycobacteria", "tuberculosis", "nontuberculous" or "NTM". All relevant abstracts were screened independently by two researchers. The final reference list was generated based on relevance to the topics covered in this review. Only papers published in English were included. Accelerator program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

All authors declare no competing or conflicting interests. 

The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis

NTM drug discovery: status, gaps and the way forward

Non-opsonic recognition of Mycobacterium tuberculosis by phagocytes

Limited role of the Tolllike receptor-2 in resistance to Mycobacterium avium

Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection

Host response to nontuberculous mycobacterial infections of current clinical importance

Elevated mitogen-activated protein kinase signalling and increased macrophage activation in cells infected with a glycopeptidolipid-deficient Mycobacterium avium

Mycobacterium abscessus Glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF-alpha by preventing interaction with TLR2

Mycobacterium tuberculosis subverts the TLR-2-MyD88 pathway to facilitate its translocation into the cytosol

The acylation state of mycobacterial lipomannans modulates innate immunity response through toll-like receptor 2

Stimulation through CD40 and TLR-4 is an effective host directed therapy against Mycobacterium tuberculosis

NOD-2 and TLR-4 signaling reinforces the efficacy of dendritic cells and reduces the dose of TB drugs against Mycobacterium tuberculosis

Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response

Triggering through Toll-like receptor 2 limits chronically stimulated T-helper type 1 cells from undergoing exhaustion

Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis

Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors

MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection

MiR-23a-5p modulates mycobacterial survival and autophagy during mycobacterium tuberculosis infection through TLR2/MyD88/NF-kappaB pathway by targeting TLR2

Function, structure and regulation of the vacuolar (H+)-ATPases

The lysosome as a cellular centre for signalling, metabolism and quality control

Fighting persistence: how chronic infections with Mycobacterium tuberculosis Evade T cell-mediated clearance and new strategies to defeat them

Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification

Host-directed therapeutics for tuberculosis: can we harness the host?

Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis

Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages

Targeting drug-sensitive and -resistant strains of Mycobacterium tuberculosis by Inhibition of Src family kinases lowers disease burden and pathology. mSphere

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials

Mycobacterium tuberculosis releases an antacid that remodels phagosomes

ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria

New insights into the evasion of host innate immunity by Mycobacterium tuberculosis

Cytoplasmic RNA sensor pathways and nitazoxanide broadly inhibit intracellular Mycobacterium tuberculosis growth

Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis

Autophagy in immunity and inflammation

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection

Autophagy: A new strategy for hostdirected therapy of tuberculosis

Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

Cutting edge: Vitamin Dmediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin

25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line

25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection

Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data

Meta-analysis of efficacy and safety of vitamin D supplementation in the treatment of pulmonary tuberculosis

Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis

High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial

High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis in mongolia: a double-blind randomised controlled trial

Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. Drug Des Dev Ther

Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3

Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages

Oral intake of phenylbutyrate with or without vitamin D-3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia

Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial

Vitamin A and D deficiencies associated with incident tuberculosis in HIV-infected patients initiating antiretroviral therapy in multinational case-cohort study

All-trans retinoic acid augments autophagy during intracellular bacterial infection

Retinoic acid and alphagalactosylceramide regulate the expression of costimulatory receptors and transcription factors responsible for B cell activation and differentiation

alpha-Galactosylceramide as a therapeutic agent for pulmonary mycobacterium tuberculosis infection

Immunotherapy added to antibiotic treatment reduces relapse of disease in a mouse model of tuberculosis

A double-blind, placebocontrolled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial

Adjunctive vitamin A and D during pulmonary tuberculosis treatment: a randomized controlled trial with a 2 × 2 factorial design. Food Function

Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis

The DNA damageregulated autophagy modulator DRAM1 links mycobacterial recognition via TLR-MYD88 to autophagic defense

Deficiency in the autophagy modulator Dram1 exacerbates pyroptotic cell death of Mycobacteria-infected macrophages

Calcium/calmodulin-dependent protein kinase Kinase 2: roles in signaling and pathophysiology

MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calciumassociated autophagy

Harnessing the mTOR pathway for tuberculosis treatment

Antimycobacterial effects of everolimus in a human granuloma model

Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy

Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis

Metformin as adjunct antituberculosis therapy

Advancing host-directed therapy for tuberculosis

Compromised metabolic reprogramming is an early indicator of CD8(+) T Cell dysfunction during chronic Mycobacterium tuberculosis infection

Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects

Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment

Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria

The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus

The tyrosine kinase inhibitor gefitinib restricts Mycobacterium tuberculosis growth through increased lysosomal biogenesis and modulation of cytokine signaling

Bazedoxifene suppresses intracellular Mycobacterium tuberculosis growth by enhancing autophagy

Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages

Suppression of autophagy and antigen presentation by Mycobacterium tuberculosis PE_PGRS47

Mycobacterium tuberculosis inhibits RAB7 recruitment to selectively modulate autophagy flux in macrophages

Organelle membrane proteomics reveals differential influence of mycobacterial lipoglycans on macrophage phagosome maturation and autophagosome accumulation

The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection

Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB

Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis

Keratinocyte growth factor administration attenuates murine pulmonary mycobacterium tuberculosis infection through granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophage activation and phagolysosome fusion

GM-CSF targeted immunomodulation affects host response to M tuberculosis infection

Disseminated mycobacterium avium complex in an adolescent with perinatally-acquired HIV infection

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine

The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIVrelated disseminated atypical mycobacterial infection

Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo

Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling

The role of nitric oxide in innate immunity

Molecular basis of mycobacterial survival in macrophages

Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88

CD157 confers host resistance to Mycobacterium tuberculosis via TLR2-CD157-PKCzeta-induced reactive oxygen species production

RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome

NAD hydrolysis by the tuberculosis necrotizing toxin induces lethal oxidative stress in macrophages

Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis

Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)

NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression

What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge

Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection

The role of nitric oxide in mycobacterial infections

Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R

Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis

L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial

Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis-a randomised trial

noxR3, a novel gene from Mycobacterium tuberculosis, protects Salmonella typhimurium from nitrosative and oxidative stress

Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates

Pathogenesis of nontuberculous mycobacteria infections

Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene

Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69loT cells in mycobacterial infection

Functional inhibition of host Histone Deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish

Host sirtuin 2 as an immunotherapeutic target against tuberculosis

Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis

Computational identification of the proteins associated with quorum sensing and biofilm formation in Mycobacterium tuberculosis

Alveolar macrophages provide an early Mycobacterium tuberculosis niche and initiate dissemination

Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling

Mycobacterium tuberculosis modulates miR-106b-5p to control cathepsin S expression resulting in higher pathogen survival and poor T-cell activation

G1-4A, a Polysaccharide from tinospora cordifolia inhibits the survival of Mycobacterium tuberculosis by modulating host immune responses in TLR4 dependent manner

Recent clinical trends in Toll-like receptor targeting therapeutics

The phytochemical bergenin enhances T Helper 1 responses and anti-mycobacterial immunity by activating the MAP kinase pathway in macrophages

Vaccines against tuberculosis: where are we and where do we need to go?

T-cell exhaustion in tuberculosis: pitfalls and prospects

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNFalpha

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis

Polarization of PPDspecific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12

IL-4 subverts mycobacterial containment in Mycobacterium tuberculosis-infected human macrophages

The immune response to Mycobacterium tuberculosis in HIV-1-coinfected persons

Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages

Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review

Effector mechanisms involved in cytokinemediated bacteriostasis of Mycobacterium avium infections in murine macrophages

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study

No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection

Immunotherapeutic effects of recombinant adenovirus encoding interleukin 12 in experimental pulmonary tuberculosis

Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection

Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset

HIV skews a balanced Mtb-specific Th17 response in latent tuberculosis subjects to a pro-inflammatory profile independent of viral load

S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis

Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis

Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor

Effective combination therapy using interferon-gamma and interleukin-2 for disseminated Mycobacterium avium complex infection in a pediatric patient with AIDS

Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare

Suppressor cell-depleting immunotherapy with denileukin diftitox is an effective host-directed therapy for tuberculosis

Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2 T cells increase resistance to tuberculosis in nonhuman primates

Cytokine-induced killer cell therapy as a promising adjunctive immunotherapy for multidrug-resistant pulmonary TB: a case report

Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection

Schlesinger LS Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses

PPARgamma is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis

NAD(+) depletion triggers macrophage necroptosis, a cell death pathway exploited by Mycobacterium tuberculosis

Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition

Pulmonary tuberculosis with acute respiratory failure

Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis

Adjunctive steroid therapy for managing pulmonary tuberculosis

cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria

TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit

TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas

Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas

Host-directed therapeutic strategies for tuberculosis

Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials

Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy

A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis

Regulation of lipid peroxidation and ferroptosis in diverse species

Selenium utilization by GPX4 Is required to prevent hydroperoxide-induced ferroptosis

Immunometabolism during Mycobacterium tuberculosis Infection

FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity

ATP exhibits antimicrobial action by inhibiting bacterial utilization of ferric ions

Anti-Mycobacterium avium complex activity of clarithromycin, rifampin, rifabutin, and ethambutol in combination with adenosine 5'-triphosphate

Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection

Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes

Small molecule mediated restoration of mitochondrial function augments anti-mycobacterial activity of human macrophages subjected to cholesterol induced asymptomatic dyslipidemia

Adjunctive hostdirected therapy with statins improves tuberculosis-related outcomes in mice

Mycobacterium tuberculosis and the macrophage: maintaining a balance

Cholesterol depletion in Mycobacterium avium-infected macrophages overcomes the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome-derived autophagic vacuoles

Statin adjunctive therapy shortens the duration of TB treatment in mice

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation

Simvastatin enhances the immune response against Mycobacterium tuberculosis

Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by LTB4 reduction but not PGE2 increment

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

Hostdirected therapies for bacterial and viral infections

Leukotriene A4 hydrolase genotype and HIV infection influence intracerebral inflammation and survival from tuberculous meningitis

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis

Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis

A beneficial effect of low-dose aspirin in a murine model of active tuberculosis

Thrombocyte inhibition restores protective immunity to mycobacterial infection in zebrafish

Use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study

Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial

Aspirin antagonism in isoniazid treatment of tuberculosis in mice

T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma

Mechanisms of granuloma formation in murine Mycobacterium avium infection: the contribution of CD4+ T cells

Cutaneous infections due to atypical mycobacteria

The granuloma in tuberculosis: dynamics of a host-pathogen collusion

Inhibition of tissue matrix metalloproteinases interferes with mycobacterium tuberculosis-induced granuloma formation and reduces bacterial load in a human lung tissue model

Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis

Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis

Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis

MMP-1 drives immunopathology in human tuberculosis and transgenic mice

Matrix metalloproteinase inhibition in a murine model of cavitary tuberculosis paradoxically worsens pathology

Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis

Matrix degradation in human immunodeficiency virus type 1-associated tuberculosis and tuberculosis immune reconstitution inflammatory syndrome: a prospective observational study

Host-directed therapies offer novel opportunities for the fight against tuberculosis

Title: role of matrix metalloproteinase -9 in progression of tuberculous meningitis: a pilot study in patients at different stages of the disease

Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis

Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases

Hypoxia promotes Mycobacterium tuberculosis-specific upregulation of granulysin in human T cells

Cyclopropane modification of trehalose dimycolate drives granuloma angiogenesis and mycobacterial growth through vegf signaling

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery

Interception of host angiogenic signalling limits mycobacterial growth

Infection-induced vascular permeability aids mycobacterial growth

Pharmacokinetic interactions with rifampicin : clinical relevance

Compromised metabolic reprogramming is an early indicator of CD8(+) T cell dysfunction during Chronic Mycobacterium tuberculosis Infection

Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model

Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus

Verapamil improves the activity of bedaquiline against Mycobacterium abscessus in vitro and in macrophages

Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux

In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis

Host-directed therapy to combat mycobacterial infections